Posted by Michael Wonder on 24 Jun 2023
Highlights from the 19-22 June 2023 CHMP meeting
23 June 2023 - The EMA’s CHMP recommended two medicines for approval at its June 2023 meeting.
The committee recommended granting a marketing authorisation for Aquipta (atogepant monohydrate), intended for the prophylaxis of migraine in adults who have at least four migraine days per month.
